2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Colorectal Neoplasms
408
Rectal Neoplasms
152
Colonic Neoplasms
150
Pancreatic Neoplasms
112
Stomach Neoplasms
110
Neoplasm Metastasis
87
Neoplasms
74
Esophageal Neoplasms
60
Small Cell Lung Carcinoma
45
Neuroblastoma
42
Lung Neoplasms
42
Glioblastoma
38
Carcinoma, Non-Small-Cell Lung
38
Brain Neoplasms
33
Esophageal Squamous Cell Carcinoma
32
Unspecified Adult Solid Tumor, Protocol Specific
31
Glioma
31
Breast Neoplasms
28
Central Nervous System Neoplasms
27
Adenocarcinoma Of Esophagus
27
Sarcoma
26
Gliosarcoma
22
Astrocytoma
22
Rhabdomyosarcoma
21
Sarcoma, Ewing
18
Adenocarcinoma
18
Gastrointestinal Neoplasms
17
Oligodendroglioma
16
Recurrence
14
Biliary Tract Neoplasms
14
Interventions
Carboplatin
7
Trastuzumab
6
Docetaxel
5
pembrolizumab
4
Paclitaxel
4
Oxaliplatin
4
Fluorouracil
4
Cytarabine
4
Cyclophosphamide
4
Azacitidine
4
pertuzumab
3
Radiotherapy
3
Observation
3
Neoadjuvant Therapy
3
Epirubicin
3
Endoscopy
3
Cisplatin
3
Chemoradiotherapy
3
Capecitabine
3
venetoclax
2
toripalimab
2
sargramostim
2
olaparib
2
durvalumab
2
cc-486
2
Tretinoin
2
Surgical Procedures, Operative
2
Standard of Care
2
Pemetrexed
2
Monatide (IMS 3015)
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Irinotecan
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT07472868
2026-03-16
MEND-IT II
Catharina Ziekenhuis Eindhoven
Phase 3
Not yet recruiting
394 enrolled